Flavonoids have been described as promising clinical agents due to their relatively low toxicity in vivo, as well as their pleiotropic effect on various biochemical pathways involved in cancer resistance, including apoptosis (CK2, PI3K/AKT and ERK signaling), autophagy (AMPK kinase activation), and senescence (p16INK4, p21CIP1, p27KIP1) [25]. This evidence concerns the gene CDKN2A and cancer.